Chengdu Baiyu Pharmaceutical Co., Ltd.

Management Team

Yonggang Wei PhD
General Manager

Dr. Wei joined Baiyu in June 2019.
He was appointed to lead the Research and Development of innovative drugs as the
General Manager of the Innovative R&D center.

Dr. Wei obtained his PhD in Organic Chemistry from the University of Wisconsin-Madison.
He published nearly 200 new drug invention patents, led 1 first-in-class drug NDA and six first-in-class drugs to clinical stage.
He won the honors of Sichuan Tianfu Qingcheng expert and Sichuan overseas high-level talent.

Technology Platform

DNA Damage Response Platform

DNA damage is a common life phenomenon.

Cells constantly deal with damage to their DNA that can originate from endogenous processes, such as DNA
replication stress, or exogenous exposures such as ionizing radiation and chemotherapy drugs, and failure to
repair damage can have devastating cellular consequences.

To counter this threat, Cells have therefore developed intricate repair mechanisms to deal with the different
types of possible DNA lesions that arise, collectively called the DNA damage response, detect DNA damage
and mediate it's repair. Most current chemotherapy and radiation treatments work by damaging DNA.
Upregulation of the DDR pathway provides tumor cells with a means to avoid damage and resist death.

Thus, combining the chemotherapy and/or radiotherapy with drugs that target DNA repair mechanisms could
overcome cancer’s resistance to treatment.

DNA Damage Response Platform

01 Robust and highly selectivity

02 Tumor tissue-specific killing

03 Make chemoradiotherapy more effective while reducing the harmful effects

04 Broad-spectrum antitumor activity

Immuno-oncology Platform

Advantages of Baiyu's

immuno-oncology platform

01 Highly selectivity

02 Better PK Features

03 Activate the immune microenvironment to cure tumors

04 Form specific immune memory to prevent tumor recurrence

05 Higher safety

Cancer immunotherapy, also known as immuno-oncology, is a form of cancer treatment that uses the power of the body’s own immune system to prevent, control, and eliminate cancer. The rapid development of modern immunotherapeutics fulfills everal clinical needs, but there are still some limitations.

For example, the percentage of patients with cancer who may benefit from and respond to PD-1/PD-L1 inhibitors does not exceed 30%, and acquired drug resistance is prone to occur; For cold tumors (such as tumors lacking T cell infiltration) or immunosuppressive TME (tumor microenvironment) tumors, the response rate of current immunotherapeutics is low、high therapy costs and the way of administration is inconvenient, etc.

To address these challenges, Baiyu is exploring new therapeutic modalities to activate the immune microenvironment and counter multiple tumor escape mechanisms to overcome the limitations of current immunotherapy.

PROTAC Platform

Based on the specific chemical molecular structure library of BAIYU, with the purpose of discovering compounds with robust degradation activity, high selectivity and strong druggability, we strive to break through the problems of "undruggable" and "drug resistance" of traditional target proteins. Currently，BAIYU PROTAC Platform has obtained multiple preclinical candidate compounds.

Development Pipeline

Program Introduction

BY101298

One of the most important functions of DNA-PK is to participate in the DNA damage repair response. DNA-PK inhibitors enhance the effect of chemoradiotherapy by inhibiting the DNA damage repair pathway. BY101298 can be used in combination with chemoradiotherapy to enhance the efficacy of chemoradiotherapy.

BY101298 is the first highly selective DNA-PK inhibitor in China independently developed by BAIYU, which has good safety profile and significantly enhances the anti-tumor efficacy of chemoradiotherapy.

BY101921

Cooperation

We look forward to building flexible, collaborative and inclusive forms of
cooperation with the global partners to promote the early and successful launch of
innovative drugs.

Welcome to contact:bd@baiyu.cn